← Browse by Condition
Medical Condition

pancreatic ductal adenocarcinoma pdac

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for pancreatic ductal adenocarcinoma pdac sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic ductal adenocarcinoma pdac Clinical Trials

How many clinical trials are currently recruiting for pancreatic ductal adenocarcinoma pdac?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for pancreatic ductal adenocarcinoma pdac, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic ductal adenocarcinoma pdac?
pancreatic ductal adenocarcinoma pdac research spans Phase 1 (2 trials), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic ductal adenocarcinoma pdac clinical trial?
Eligibility criteria for pancreatic ductal adenocarcinoma pdac trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Phase 3
1
Top Sponsors
Revolution Medicines, Inc. 2 trials
Imperial College London 1 trial
Shenzhen Xinhe Biomedical 1 trial
IRCCS San Raffaele 1 trial

Recruiting Clinical Trials

NCT07714538
Recruiting
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
Enrollment
1,000 pts
Location
United Kingdom
Sponsor
Imperial College London
View Trial →
NCT05379985 Phase 1, Phase 2
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Enrollment
754 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT07594964 Phase 1
Recruiting
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Enrollment
48 pts
Location
China
Sponsor
Shenzhen Xinhe Biomedical
View Trial →
NCT07491445 Phase 3
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment
900 pts
Location
United States, Austr...
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT04622423
Recruiting
Advanced Therapies for Liver Metastases
Enrollment
625 pts
Location
Italy
Sponsor
IRCCS San Raffaele
View Trial →

Related Conditions

hepatocellular carcinoma hcc (2) colorectal cancer crc (2) oesophageal squamous cell carcinoma (1) oesophageal adenocarcinoma (1) gastric adenocarcinoma (1) cholangiocarcinoma (1) colorectal adenocarcinoma (1) non small cell lung cancer nsclc (1) advanced solid tumors (1) biliary cancer cholangiocarcinoma gall bladder cancer (1) gastric cancer gc (1) pancreatic cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology